Abstract: A MALDI ion source is disclosed comprising: a target plate (2) having a front surface (4), a rear surface (6), and at least one sample receiving well (9) for receiving a liquid sample or at least one sample receiving channel (8) extending from an opening (12) in the rear surface (6) to an opening (14) in the front surface (4) for receiving a liquid sample (10), wherein each well (9) or channel (8) has a volume of ?1 ?L. The ion source also comprise a laser (16) for ionising a liquid sample (10) on or in the target plate (2), wherein the laser (16) is a pulsed laser set up and configured to have a pulsed repetition rate of ?20 Hz, or is a continuous laser.

Abstract: A method of mass or ion mobility spectrometry is disclosed that uses the Leidenfrost effect to cause a liquid to be repelled away from a heated surface so as to levitate above there-above. The repelled liquid is urged so as to move along the surface in a predetermined direction, for example, by the geometric configuration of the heated surface.

Abstract: A method of producing ions from a sample is disclosed. The method comprises directing a spray of droplets onto a sample, and causing droplets comprising analyte from the sample to impact upon a surface so as to generate analyte ions.

Abstract: A novel assay and a suite of devices may isolate nucleic acids from prokaryotic and eukaryotic cells and prepare samples for real-time (quantitative) polymerase chain reaction (PCR) analysis. The assay may employ an aqueous-based non-alcohol approach that yields robust RNA quality. The suite of ready-to-use devices may provide pre-loaded reagents in liquid and lyophilized formats to enable rapid manual operation in a laboratory or remote field environments. The assay and devices may be particularly suitable to analysis in microgravity or deep space environments.

Abstract: The present disclosure provides for identification of recurring transactions to transfer to a financial institution. Potential service providers that may provide services to a user are identified based on received user information. A selection of service providers from a list of the identified potential service providers is received and recurring transactions are identified between the user and the selected service providers. The identified recurring transactions are exported to the financial institution.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: QCVQGYRA and RWTQPQLICTG on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Abstract: Disclosed herein are various methods and apparatus for performing charge detection mass spectrometry (CDMS). In particular, techniques are disclosed for monitoring a detector signal from a CDMS device to determine how many ions are present in the ion trap (10) of the CDMS device. For example, if no ions are present the measurement can then be terminated early. Similarly, if more than one ion is present, the measurement can be terminated early, or ions can be removed from the trap (10) until only a single ion remains. Techniques are also provided for increasing the probability of there being a single ion in the trap (10). A technique for attenuating an ion beam is also provided.

Abstract: A method of ionising a sample is disclosed comprising nebulising a sample which includes monoclonal antibody (“mAb”) molecules. A stream of monoclonal antibody droplets or charged droplets is directed so as to impact upon a target or electrode so as to form intact parent monoclonal antibody ions, intact minus light chain parent monoclonal antibody ions or light chain (“LC”) fragment monoclonal antibody ions.

Abstract: A mechanism for transferring loads characterized by a frame adapted to be mounted on a lift mechanism of a lift truck, having a pair of telescopic rails mounted at one end to the frame. The telescopic rails extending parallel to one another, extendable laterally of the lift mechanism of the lift truck, between retracted and extended positions by an actuator that moves the telescopic rails. A carriage is mounted on the telescopic rails for movement there along when the telescopic rails are in their extended positions and the free ends of the telescopic rails are supported. The carriage having a secondary lift mechanism mounted thereon by which a load may be raised and lowered relative to the carriage.

Abstract: A data warehouse engine (DWE) includes a central processing unit (CPU) core and a first data organization unit (DOU), where the first DOU is configured to aggregate read operations. The DWE also includes a first command queue coupled between the CPU core and the first DOU, where the first command queue is configured to convey commands from the CPU core to the first DOU.

Abstract: Devices and methods for the efficient disaggregation of tissue samples, separating the tissue into individual intact cells or small aggregates of cells for analysis. A device may include a chamber to receive fluid and a tissue specimen containing more than one cell to be disaggregated. The chamber may include an opening and an agitator in fluid contact with the fluid and the tissue specimen. The agitator may include a micromotor which provides rotational motion to a shaft and an impeller fixed to the shaft such that the impeller and the shaft rotate together upon provision of the rotational motion by the micromotor. The device may include an electrical energy source electrically coupled to the micromotor to rotate the impeller sufficient to disaggregate the one or more individual cells from the tissue specimen and in a manner which does not lyse the one or more individual cells.

Abstract: A computation system-on-a-chip (CSoC) includes a first scalable distributed real-time Data Warehousing (sdrDW) engine and a network interface coupled to the first sdrDW engine, where the network interface is coupled to an interconnect, and where the CSoC is configured to transmit a task request over the interconnect to a first networked bulk storage controller (NBSC) requesting that a task be performed on a bulk storage medium.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Abstract: A vehicle attachment apparatus, including an elongated member removably connected to a hitch of a vehicle, an umbrella removably connected to the elongated member to provide shade for a user that is positioned under the umbrella, and a seat attachment removably connected to the elongated member to support the user seated thereupon.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.